GlassScriptPhysician profile
Peter L Nguy
NPI 1932632395
$1,919.90
in general payments reported to CMS, 2019-2025
13 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.79 · 2023: $684 · 2024: $635 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $599.93 | 2023-2025 | Inspire |
| Genzyme Corporation | $511.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.41 | 2022-2024 | Nucala |
| Hologic Sales and Service, LLC | $153.35 | 2023-2024 | Coolseal Generator |
| Csl Behring | $150.20 | 2024-2025 | Andembry, Haegarda |
| Optinose US, INC. | $81.34 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.90 | 2023-2024 | Takhzyro |
| Biocryst US Sales Co., LLC | $58.77 | 2023-2024 | Orladeyo |
| Pharming Healthcare, INC. | $28.65 | 2023 | Ruconest |
| Merck Sharp & Dohme LLC | $25.82 | 2023 | |
| Genentech USA, INC. | $24.66 | 2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2022 | |
| Phadia US INC. | $18.81 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nguy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.